Trials / Completed
CompletedNCT07031674
Comparing Efficacy and Safety of Telitacicept and Belimumab in Lupus Nephritis: A Retrospective Multicenter Cohort Study.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 56 (actual)
- Sponsor
- Yipeng Liu · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this observational study is to compare the efficacy and safety of telitacicept and belimumab in the treatment of lupus nephritis in patients aged 18-65 years with lupus nephritis. The main question it aims to answer is: What are the response rates of the two drugs for the main renal therapy in the lupus nephritis population? Which drug has better efficacy and safety? This study is a retrospective study. The participants will not receive any treatment.
Conditions
Timeline
- Start date
- 2025-10-01
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
- First posted
- 2025-06-22
- Last updated
- 2026-02-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07031674. Inclusion in this directory is not an endorsement.